Manish Bais, DVM, PhD
Associate Professor
Boston University Henry M. Goldman School of Dental Medicine
Translational Dental Medicine

PhD, Indian Veterinary Research Institute (IVRI)
DVM, Nagpur Veterinary College
MVSc, Indian Veterinary Research Institute (IVRI)
BVSc, Nagpur Veterinary College



Dr. Manish Bais is a Research Assistant Professor in the Department of Molecular and Cell Biology at Boston University’s Henry M. Goldman School of Dental Medicine. Dr. Bais is also an important member of the Oral Cancer Research Initiative (OCRI). With funding from the OCRI, Dr. Bais travelled to the National Institute of Dental and Craniofacial Research in the summer of 2013 to receive mouse model training in the lab of Dr. Roberto Weigert. Dr. Bais has made large contributions to the initiative with the development of an orthotropic oral cancer mouse model.

The orthotropic nude mouse models of non-metastatic and metastatic tongue cancer that Dr. Bais has developed will facilitate mechanistic in vivo studies and preclinical testing of novel targets for anti-oral cancer therapy. Specifically, he has generated mice with non-metastatic tongue tumors following injection of human tongue squamous cell carcinoma (OSCC) CAL27 cells into tongues of nude mice. In addition, Dr. Bais has generated mice with tongue tumors formed by injection of SCC2 cells that metastasize to lung, bone and liver, sites of metastases of human tongue cancers.

Dr. Bais is collaborating with many OCRI investigators including Dr. Maria Kukuruzinska, Dr. Philip Trackman, Dr. Bob Varelas and Dr. David Sherr. This animal model and other models still in progress can help us to better understand the biology of oral cancer as well as provide new therapeutic opportunities in the treatment of this deadly disease.

Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Evans Center for Interdisciplinary Biomedical Research


Member
Boston University
Genome Science Institute


Research Associate Professor
Boston University Henry M. Goldman School of Dental Medicine
Molecular & Cell Biology




Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
03/15/2022 - 01/31/2027 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R01DE031413-03

Epigenetic Targeting of LSD1 OSCC for Therapy
09/01/2018 - 08/31/2021 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R21DE026892-02

LOXL2 in Temporomandibular Joint Osteoarthritis
08/01/2015 - 07/31/2018 (PI)
NIH/National Institute of Dental & Craniofacial Research
5R03DE025274-02



Title


Yr Title Project-Sub Proj Pubs
2025 Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy 5R01DE031413-04
2024 Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy 3R01DE031413-02S1
2024 Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy 5R01DE031413-03
2024 Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy 3R01DE031413-03S1
2023 Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy 5R01DE031413-02
2022 Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy 1R01DE031413-01
2019 Epigenetic targeting of LSD1 for OSCC Therapy 5R21DE026892-02 1
2018 Epigenetic targeting of LSD1 for OSCC Therapy 1R21DE026892-01A1 1
2016 LOXL2 in Temporomandibular Joint Osteoarthritis 5R03DE025274-02 6
2015 LOXL2 in Temporomandibular Joint Osteoarthritis 1R03DE025274-01 6

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Raut R, Chakraborty A, Neogi T, Albro M, Snyder B, Schaer T, Zhang C, Grinstaff M, Bais M. Constructing a cross-tissue human knee single-cell atlas identified osteoarthritis reduces regenerative tissue stem cells while increasing inflammatory pain macrophages. Res Sq. 2025 May 05.View Related Profiles. PMID: 40386432; PMCID: PMC12083644; DOI: 10.21203/rs.3.rs-6247502/v1;
     
  2. Chakraborty AK, Raut RD, Iqbal K, Choudhury C, Alhousami T, Chogle S, Acosta AS, Fagman L, Deabold K, Takada M, Sahay B, Kumar V, Bais MV. Lysine-specific demethylase 1 controls key OSCC preneoplasia inducer STAT3 through CDK7 phosphorylation during oncogenic progression and immunosuppression. Int J Oral Sci. 2025 Apr 17; 17(1):31.View Related Profiles. PMID: 40246812; PMCID: PMC12006301; DOI: 10.1038/s41368-025-00363-x;
     
  3. Raut R, Srivastava D, Nayak V, Saini T, Gupta P, Chakraborty AK, Choudhury C, Bais MV, Mishra P, Misra A. Clinical data investigation identifies MARK3 as an oncogenic driver in castration-resistant prostate cancer. Biochem Biophys Rep. 2025 Jun; 42:102003.View Related Profiles. PMID: 40248134; PMCID: PMC12004708; DOI: 10.1016/j.bbrep.2025.102003;
     
  4. Chakraborty AK, Kroehling L, Raut RD, Choudhury C, Kukuruzinska M, Gutkind JS, Varelas X, Sahay B, Monti S, Bais MV. LSD1 inhibition corrects dysregulated MHC-I and dendritic cells activation through IFN?-CXCL9-CXCR3 axis to promote antitumor immunity in HNSCC. bioRxiv. 2025 Mar 17.View Related Profiles. PMID: 40166238; PMCID: PMC11956948; DOI: 10.1101/2025.03.17.643710;
     
  5. DeMoya CD, Joenathan A, Lawson TB, Felson DT, Schaer TP, Bais M, Albro MB, Mäkelä J, Snyder BD, Grinstaff MW. Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy. Nat Rev Rheumatol. 2024 Jul; 20(7):432-451.View Related Profiles. PMID: 38858605; PMCID: PMC11348290; DOI: 10.1038/s41584-024-01125-5;
     
  6. Stewart HL, Gilbert D, Stefanovski D, Garman Z, Albro MB, Bais M, Grinstaff MW, Snyder BD, Schaer TP. A missed opportunity: A scoping review of the effect of sex and age on osteoarthritis using large animal models. Osteoarthritis Cartilage. 2024 May; 32(5):501-513.View Related Profiles. PMID: 38408635; PMCID: PMC11534084; DOI: 10.1016/j.joca.2024.02.009;
     
  7. Lee VK, Lee T, Ghosh A, Saha T, Bais MV, Bharani KK, Chag M, Parikh K, Bhatt P, Namgung B, Venkataramanan G, Agrawal A, Sonaje K, Mavely L, Sengupta S, Mashelkar RA, Jang HL. An architecturally rational hemostat for rapid stopping of massive bleeding on anticoagulation therapy. Proc Natl Acad Sci U S A. 2024 Jan 30; 121(5):e2316170121. PMID: 38252814; PMCID: PMC10835033; DOI: 10.1073/pnas.2316170121;
     
  8. Reed ER, Jankowski SA, Spinella AJ, Noonan V, Haddad R, Nomoto K, Matsui J, Bais MV, Varelas X, Kukuruzinska MA, Monti S. ß-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer. Transl Res. 2023 Oct; 260:46-60.View Related Profiles. PMID: 37353110; PMCID: PMC10527608; DOI: 10.1016/j.trsl.2023.05.007;
     
  9. Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V, Campbell JD, Noonan V, Hanna GJ, Denis GV, Monti S, Kukuruzinska MA, Varelas X, Bais MV. Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. Mol Cancer Res. 2022 May 04; 20(5):712-721.View Related Profiles. PMID: 35105672; PMCID: PMC9081163; DOI: 10.1158/1541-7786.MCR-21-0310;
     
  10. Joshi VG, Chindera K, Bais MV, Sajjanar B, Tiwari AK, Kumar S. Novel peptide (RATH) mediated delivery of peptide nucleic acids for antiviral interventions. Appl Microbiol Biotechnol. 2021 Sep; 105(18):6669-6677. PMID: 34427763
     
Showing 10 of 44 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 44 publications over 21 distinct years, with a maximum of 7 publications in 2017

YearPublications
20032
20041
20071
20081
20093
20101
20111
20121
20132
20144
20154
20161
20177
20181
20192
20202
20211
20221
20231
20243
20254


Could Blocking Or Deleting A Protein Help Prevent Common Oral Cancers?

Medical Dialogues 6/2/2022

Could blocking or deleting a protein help prevent common oral cancers?

Medical Xpress 4/26/2022

2015-2017 RO3- NIH/ NIDCR: LOXL2 in TMJ osteoarthritis
2015-2016 Henry M. Goldman School of Dental Medicine: Lysine specific demethylase 1 inhibitor for improved personalized oral cancer therapy
2014-2015 CNN Pilot grant, Center for Nanoscience and Nanotechnology (CNN), Boston University: Nanodelivery Approaches for Targeting DPAGT1 and LSD1 for oral Squamous Cell Carcinoma therapy
2014-2015 CTSI, BUSDM: Patient-derived Tumors Orthotopic Oral Cancer Mouse Models
2012-2013 BUSDM seed funding: LOXL2 in Anabolic Response to TMJ-Osteoarthritis
Contact for Mentoring:

700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Google Map

617.358.4439
Download vCard

Bais's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (249) concept(s)
_
Media Mentions
_
Co-Authors
See all (33) people
_
Similar People
See all (60) people
_
Same Department
Search Department